Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)NewsBilanz/GuVDividende/HVZertifikateDepot/Watchlist
Times + SalesChart-AnalyseAnalysenSchätzungenTermineOptionsscheinemyHome
BörsenplätzeChartvergleichKurszieleVergleichProfilKnock-OutsSenden
OrderbuchRealtime Stuttgart  InsidertradesFonds 
HistorischRealtime PushmyNews im ForumAnleihen
Kaufen
Verkaufen
  • Sprache:
  • Alle
  • DE
  • EN
  • Sortieren:
  • Datum
  • meistgelesen
30.06.15
Onxeo: Validive® at the MASCC/ISOO International Symposium: Oral Presentation of Phase II Trial Results and Meeting with Its International Advisory Board (Businesswire)
23.06.15
Onxeo : Beleodaq® (belinostat) Pivotal BELIEF Study Results Published in the Journal of Clinical Oncology (JCO) (Businesswire)
18.06.15
Onxeo Consolidates Its Industrial Property with a US Patent Protecting Validive® until 2029 (Businesswire)
04.06.15
Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at May 31, 2015 (Businesswire)
03.06.15
Onxeo Meets US Investors During "French Life Sciences Days” Event in New York on June 17 & 18, 2015 (Businesswire)
28.05.15
Onxeo Announces Preclinical & Clinical Data from Three Studies Supporting the Potential For Belinostat in Multiple Orphan Oncology Indications (Businesswire)
26.05.15
Onxeo Announces Final Data from Completed Phase II Trial of Validive® for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients (Businesswire)
20.05.15
Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at April 30, 2015 (Businesswire)
20.05.15
Onxeo’s Combined General Meeting of Shareholders (Businesswire)
12.05.15
Onxeo S.A.: Publication of a Letter to Shareholders – May 2015 (Businesswire)
06.05.15
Onxeo : Oral Presentation of Phase II Trial Results of Validive® at the MASCC/ISOO International Symposium (Businesswire)
20.04.15
Onxeo: Belinostat Abstracts for American Association for Cancer Research 2015 (Businesswire)
16.04.15
Onxeo S.A.: ReLive: investigators meeting and E-poster of the study design during the 2015 EASL congress (Businesswire)
15.04.15
Onxeo: Annual General Shareholders’ Meeting: Results and Convening to a New Meeting (Businesswire)
15.04.15
Onxeo S.A.: Quarterly Information as of March 31, 2015 (Businesswire)
14.04.15
Onxeo S.A.: Publication of 2014 Reference Document and Annual Report (Businesswire)
13.04.15
Onxeo: Cipher Pharmaceuticals Acquires INNOCUTIS Holdings, Licensee of Sitavig® in the USA (Businesswire)
13.04.15
Onxeo Announces 6th Positive DSMB Recommendation for Livatag® ReLive Study in HCC (Businesswire)
09.04.15
Onxeo: Belinostat Phase I/II Results in Soft Tissue Sarcoma to Be Presented at the 2015 Annual ASCO Meeting (Businesswire)
02.04.15
Onxeo S.A.: Phase II trial results of Validive® presented at the ASCO Conference (Businesswire)
02.04.15
Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at March 31, 2015 (Businesswire)
31.03.15
Onxeo S.A.: Judith Greciet, invited as guest speaker at international Allicense Conference (Businesswire)
26.03.15
Onxeo Expands Livatag® International Phase III Clinical Trial "ReLive” to 3 New Countries (Businesswire)
25.03.15
Onxeo: Combined Ordinary and Extraordinary General Meeting on April 15, 2015 (Businesswire)
18.03.15
ONXEO Consolidates Its Intellectual Property with the Grant of New Patent Protection of Validive® in Japan Until 2029 (Businesswire)
05.03.15
Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at February 28, 2015 (Businesswire)
04.03.15
2014 Onxeo Review and 2015 Perspectives (Businesswire)
10.02.15
Onxeo Strengthens Its Executive Management Team (Businesswire)
06.02.15
Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at January 31, 2015 (Businesswire)
28.01.15
Onxeo S.A.: Publication of a Shareholders Letter (Businesswire)
26.01.15
Onxeo’s Shares Transferred to Compartment B on Euronext Paris (Businesswire)
16.01.15
Onxeo Announces Its Financial Calendar for 2015 (Businesswire)
08.01.15
Onxeo to Present at Biotech Showcase™ Annual Conference during JP Morgan Healthcare Conference (Businesswire)
07.01.15
Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at December 31, 2014 (Businesswire)
16.12.14
Onxeo Announces the Realization of Its Share Capital Increase with Shareholders’ Preferential Subscription Rights (Businesswire)
12.12.14
Onxeo Announces the Great Success of Its Share Capital Increase with Shareholders’ Preferential Subscription Rights (Businesswire)
03.12.14
Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2014 (Businesswire)
24.11.14
Onxeo Announces Positive DSMB Recommendation for Its Phase III Trial with Livatag® in Primary Liver Cancer (Businesswire)
18.11.14
ONXEO Launches a Rights Issue with Shareholder Preferential Subscription Rights, for a Maximum Amount of up to €41.6 Million (Including an Extension Clause of €5.3 Million) (Businesswire)
13.11.14
Onxeo Confirms Receipt of the $25M Milestone Payment on Beleodaq® (Businesswire)
Seite: 1234

Bioalliance PharmaAct Nom Cat-P News

Bioalliance PharmaAct Nom Cat-P News: auf dieser Seite finden Sie alle Bioalliance PharmaAct Nom Cat-P News und Nachrichten zur Bioalliance PharmaAct Nom Cat-P Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Bioalliance PharmaAct Nom Cat-P News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Bioalliance PharmaAct Nom Cat-P News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Meistgelesene Bioalliance PharmaAct Nom Cat-P News

Bioalliance PharmaAct Nom Cat-P Peer Group News

Keine Nachrichten gefunden.